A Study of SHR6508 in Secondary Hyperparathyroidism
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Secondary Hyperparathyroidism
DRUG: SHR6508|DRUG: SHR6508|DRUG: Cinacalcet
Change From Baseline in serum iPTH, iPTH was tested at a central laboratory., Baseline and the efficacy period, defined as Week 16
Proportion of Participants to End of Study whose iPTH decreased byâ‰¥30% from baseline, iPTH was tested at a central laboratory., Baseline and the efficacy period, defined as Week 16|Proportion of Participants to End of Study whose iPTH decreased to 300 pg/mL from baseline, iPTH was tested at a central laboratory., Baseline and the efficacy period, defined as Week 16|Change From Baseline in serum cCa and P, cCa and P were tested at a local laboratory., Baseline and the efficacy period, defined as Week 16|Participants With Treatment-Emergent Adverse Events (TEAEs), Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA), Day1 to End of Study, End of Study is about Week 20|Participants with Anti-SHR6508 Antibody at baseline and postbaseline, Day1 to End of Study, End of Study is about Week 20
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.